A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Latest Information Update: 03 Apr 2026
At a glance
- Drugs JL-15003 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors JECHO Biopharmaceuticals
Most Recent Events
- 03 Apr 2026 New trial record